Retinoblastoma Protein Loss in p53 Abnormal Endometrial Carcinoma: Histologic and Clinicopathological Correlates
Modern Pathology · 2025
DOI: 10.1016/j.modpat.2024.100660 ↗Kurz gefasst
Fachartikel in der Zeitschrift Modern Pathology, 2025. Verfasst von Ezgi Dicle Serbes und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Van Research and Training Hospital, Van, Turkiye. Hauptthemen laut MEDLINE: Endometrial Neoplasms, Retinoblastoma Protein, Tumor Suppressor Protein p53, Biomarkers, Tumor. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Dutch Cancer Society.
Abstract (Originalsprache)
Of the 4 molecular subtypes of endometrial cancer (EC), p53-abnormal (p53abn) EC is associated with abundant copy number alterations and the worst clinical outcome. Patients with p53abn EC have the highest risk of disease recurrence and death, independent of tumor grade and histologic subtype. Currently, all invasive p53abn ECs are considered high risk, and no prognostic biomarkers have yet been found that can aid in clinical management. Here, we aimed to test whether loss of retinoblastoma (RB) protein expression using immunohistochemistry has the potential for prognostic refinement of p53abn EC. A large cohort of 227 p53abn ECs collected from the PORTEC-1/2/3 clinical trials and the Medisch Spectrum Twente cohort study was investigated, and RB loss was identified in 7.0% (n = 16/227). RB-lost p53abn ECs were predominantly high-grade endometrioid ECs (n = 6, 37.5%) and carcinosarcomas with endometrioid-type epithelial component (n = 5, 31.3%). Histologically, RB-lost p53abn ECs were typified by high-grade nuclear atypia (n = 16, 100%), predominantly solid growth pattern (n = 15/16, 93.8%), and polypoid growth (n = 9/16, 56.3%). Copy number loss involving the RB1 locus was identified in the majority of RB-lost p53abn EC (n = 13/14, 92.9%), explaining the loss of RB expression. Comparative analysis also showed that RB-lost p53abn ECs were diagnosed at earlier stages than RB-retained p53abn EC (P = .014). Interestingly, RB-lost p53abn EC showed prolonged time to overall recurrence (P = .038), even within stage I alone (P = .040). These findings highlight distinct morphomolecular features in RB-lost p53abn ECs and confirm the utility of RB immunohistochemistry as a surrogate for underlying molecular RB1 alterations. To our knowledge, this is the first study to show the potential use of RB in prognostic refinement of p53abn EC, although validation is warranted.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Van Research and Training Hospital, Van, Turkiye.
- Department of Radiation Oncology, Leiden University Medical Center, Leiden, The Netherlands.
- Division of Women's and Perinatal Pathology, Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
- Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands.
- Department of Radiation Oncology, Medisch Spectrum Twente, Enschede, The Netherlands.
- Department of Radiation Oncology, University Medical Center Utrecht, Utrecht, The Netherlands.
Förderung
- Dutch Cancer Society
Zitieren
APA
Serbes, E. D., Horeweg, N., Parra-Herran, C., van Rijnsoever, R., Jobsen, J. J., Jurgenliemk-Schulz, I., Kuijsters, N., Nout, R. A., Haverkort, M. A. D., Powell, M. E., Khaw, P., Plante, M., Genestie, C., Nijman, H. W., Creutzberg, C. L., Bosse, T., & Kramer, C. J. H. (2025). Retinoblastoma Protein Loss in p53 Abnormal Endometrial Carcinoma: Histologic and Clinicopathological Correlates. Modern Pathology. https://doi.org/10.1016/j.modpat.2024.100660
Vancouver
Serbes ED, Horeweg N, Parra-Herran C, van Rijnsoever R, Jobsen JJ, Jurgenliemk-Schulz I, et al. Retinoblastoma Protein Loss in p53 Abnormal Endometrial Carcinoma: Histologic and Clinicopathological Correlates. Modern Pathology. 2025. doi:10.1016/j.modpat.2024.100660
BibTeX
@article{Serbes2025,
author = {Serbes, Ezgi Dicle and Horeweg, Nanda and Parra-Herran, Carlos and van Rijnsoever, Renske and Jobsen, Jan J and Jurgenliemk-Schulz, Ina and Kuijsters, Nienke and Nout, Remi A and Haverkort, Marie A D and Powell, Melanie E and Khaw, Pearly and Plante, Marie and Genestie, Catherine and Nijman, Hans W and Creutzberg, Carien L and Bosse, Tjalling and Kramer, Claire J H},
title = {Retinoblastoma Protein Loss in p53 Abnormal Endometrial Carcinoma: Histologic and Clinicopathological Correlates},
journal = {Modern Pathology},
year = {2025},
doi = {10.1016/j.modpat.2024.100660}
}
EUVIMED